A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
← catalyst calendarNCT05372354 · readout in 54 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
260estimated
Sites
17
Countries
Canada, Norway, Spain +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-10-18 | actual | When the study began enrolling |
| Primary completion | 2026-10-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-10-12 | estimated | The whole study's end, after follow-up |
| First posted | 2022-05-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Myeloma
Interventions
- Drug: CC-92480 — also filed as BMS-986348
- Drug: Tazemetostat
- Drug: BMS-986158
- Drug: Trametinib
- Drug: Dexamethasone
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs)
measured From first participant first visit until 28 days after the last participant discontinues study treatment, up to approximately 4 years
Number of participants with Serious AEs
measured Up to approximately 4 years
Number of participants with AEs meeting protocol-defined DLT criteria
measured Up to approximately 4 years
Number of participants with AEs leading to discontinuation
measured Up to approximately 4 years
Number of deaths
measured Up to approximately 4 years
Establish recommended Phase 2 dose (RP2D)
measured Up to approximately 2 years
Establish dosing schedule of each combination for Part 2 Dose Expansion
measured Up to approximately 2 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed